NASDAQ:NUVA - NuVasive Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$49.76 +0.61 (+1.24 %)
(As of 05/23/2018 11:01 AM ET)
Previous Close$48.96
Today's Range$48.96 - $49.84
52-Week Range$44.62 - $81.68
Volume7,809 shs
Average Volume785,859 shs
Market Capitalization$2.54 billion
P/E Ratio25.73
Dividend YieldN/A
Beta0.39

About NuVasive (NASDAQ:NUVA)

NuVasive logoNuVasive, Inc., a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Its spine surgery product line offerings comprise products for the thoracolumbar and the cervical spine, which are primarily used to enable surgeons to access the spine and to perform restorative and fusion procedures in a minimally-disruptive fashion. Its biologics products include Osteocel Plus and Pro, a cellular bone matrix; Formagraft, a collagen-based synthetic bone substitute; AttraX, a synthetic bone graft material; and Propel DBM, a moldable demineralized bone matrix putty, which are used for spinal fusion or bone healing process. The company's IOM services are used for onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. It also provides implants used for interbody disc height restoration; and fixation products, including pedicle screws, rods, and plates. In addition, the company offers Integrated Global Alignment platform for assessing, preserving, and restoring spinal alignment; MAGEC-early onset scoliosis, a spinal bracing and distraction system; and PRECICE, a limb lengthening system. NuVasive, Inc. sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly-employed sales personnel, and distributors in the United States and internationally. The company was founded in 1997 and is headquartered in San Diego, California.

Receive NUVA News and Ratings via Email

Sign-up to receive the latest news and ratings for NUVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:NUVA
CUSIP67070410
Phone858-909-1800

Debt

Debt-to-Equity Ratio0.77
Current Ratio2.41
Quick Ratio1.30

Price-To-Earnings

Trailing P/E Ratio25.73
Forward P/E Ratio20.31
P/E Growth1.34

Sales & Book Value

Annual Sales$1.03 billion
Price / Sales2.48
Cash Flow$4.7617 per share
Price / Cash10.45
Book Value$14.87 per share
Price / Book3.35

Profitability

EPS (Most Recent Fiscal Year)$1.91
Net Income$83 million
Net Margins4.14%
Return on Equity13.14%
Return on Assets6.11%

Miscellaneous

Employees2,600
Outstanding Shares51,260,000

NuVasive (NASDAQ:NUVA) Frequently Asked Questions

What is NuVasive's stock symbol?

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

How will NuVasive's stock buyback program work?

NuVasive announced that its Board of Directors has authorized a stock buyback program on Wednesday, October 25th 2017, which permits the company to repurchase $100,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to purchase shares of its stock through open market purchases. Stock repurchase programs are generally a sign that the company's management believes its shares are undervalued.

How were NuVasive's earnings last quarter?

NuVasive, Inc. (NASDAQ:NUVA) posted its earnings results on Tuesday, May, 1st. The medical device company reported $0.39 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.45 by $0.06. The medical device company had revenue of $260.50 million for the quarter, compared to the consensus estimate of $259.43 million. NuVasive had a return on equity of 13.14% and a net margin of 4.14%. The business's revenue for the quarter was up 4.6% compared to the same quarter last year. During the same quarter last year, the company posted $0.37 earnings per share. View NuVasive's Earnings History.

When is NuVasive's next earnings date?

NuVasive is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for NuVasive.

What guidance has NuVasive issued on next quarter's earnings?

NuVasive issued an update on its FY18 earnings guidance on Tuesday, May, 1st. The company provided earnings per share (EPS) guidance of $2.44-2.47 for the period, compared to the Thomson Reuters consensus estimate of $2.46. The company issued revenue guidance of $1.095-1.105 billion, compared to the consensus revenue estimate of $1.10 billion.

What price target have analysts set for NUVA?

16 analysts have issued 12 month price objectives for NuVasive's shares. Their forecasts range from $47.00 to $90.00. On average, they expect NuVasive's stock price to reach $66.5333 in the next twelve months. View Analyst Ratings for NuVasive.

What are Wall Street analysts saying about NuVasive stock?

Here are some recent quotes from research analysts about NuVasive stock:
  • 1. Needham & Company LLC analysts commented, "NUVA’s 1Q18 revenue beat and EPS missed consensus. Management reiterated its 2018 revenue and EPS guidance. Organic revenue growth improved to 2% in 1Q18 from 0% in 4Q17 as US Spinal Hardware and biologics growth improved. NUVA’s revenue guidance requires it to accelerate its revenue growth; we believe that it can do this given new products, easing comps, and stabilization of biologics. And its EPS guidance requires a substantial improvement in its gross and operating margin; we believe it can do this with improvements in its new manufacturing plant and SG&A leverage. Unfortunately, both the revenue and margin ramps are likely to continue to make NUVA a show me" story despite its discount P/E multiple." (5/2/2018)
  • 2. According to Zacks Investment Research, "NuVasive has underperformed its industry over the past six months. The company's U.S. business has been delivering dull performance with softness in both U.S. Spinal Hardware and U.S. Surgical Support businesses. However, solid performance of the international business with more than 20% growth for the fifth consecutive quarter buoys optimism. The company’s expectation to higher adjusted operating profit margin of at least 100 bps in 2018 reflects its focus on operational efficiencies and in-house manufacturing facility. Moreover, we are upbeat about the recently-completed buyout of SafePassage. Per NuVasive, the acquisition will strengthen the company's intraoperative neuromonitoring business line. The consolidated giant is expected to deliver services to more than 1,000 customers and 3,000 surgeons." (5/1/2018)

Are investors shorting NuVasive?

NuVasive saw a drop in short interest in the month of April. As of April 30th, there was short interest totalling 5,124,933 shares, a drop of 23.8% from the April 13th total of 6,729,507 shares. Based on an average trading volume of 741,551 shares, the short-interest ratio is currently 6.9 days. Currently, 10.1% of the company's shares are sold short.

Who are some of NuVasive's key competitors?

Who are NuVasive's key executives?

NuVasive's management team includes the folowing people:
  • Mr. Gregory T. Lucier, Chairman & CEO (Age 54)
  • Mr. Matthew W. Link, Exec. VP of Strategy, Technology & Corp. Devel. (Age 43)
  • Mr. Jason Marshall Hannon, Former Pres & COO (Age 46)
  • Mr. Rajesh J. Asarpota, Exec. VP & CFO (Age 51)
  • Mr. Jereme Sylvain, Chief Accounting Officer (Age 38)

Has NuVasive been receiving favorable news coverage?

News stories about NUVA stock have trended somewhat negative this week, Accern reports. The research firm scores the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. NuVasive earned a media sentiment score of -0.19 on Accern's scale. They also assigned press coverage about the medical device company an impact score of 46.46 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are NuVasive's major shareholders?

NuVasive's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Champlain Investment Partners LLC (6.13%), Fisher Asset Management LLC (2.49%), Dimensional Fund Advisors LP (2.31%), Eagle Asset Management Inc. (2.19%), OppenheimerFunds Inc. (1.72%) and Northern Trust Corp (1.53%). Company insiders that own NuVasive stock include Gregory T Lucier, Jason Hannon, Joan Stafslien, Lesley H Howe, Matthew Link, Michael D Ohalleran, Patrick Miles and Peter Michael Leddy. View Institutional Ownership Trends for NuVasive.

Which major investors are selling NuVasive stock?

NUVA stock was sold by a variety of institutional investors in the last quarter, including State of Tennessee Treasury Department, OppenheimerFunds Inc., Scout Investments Inc., PNC Financial Services Group Inc., Eos Focused Equity Management L.P., Stevens Capital Management LP, Fisher Asset Management LLC and Eagle Asset Management Inc.. View Insider Buying and Selling for NuVasive.

Which major investors are buying NuVasive stock?

NUVA stock was purchased by a variety of institutional investors in the last quarter, including Vaughan Nelson Investment Management L.P., Rock Springs Capital Management LP, Victory Capital Management Inc., Champlain Investment Partners LLC, Hood River Capital Management LLC, Mesirow Financial Investment Management Equity Management, Dimensional Fund Advisors LP and Fort Washington Investment Advisors Inc. OH. Company insiders that have bought NuVasive stock in the last two years include Gregory T Lucier, Joan Stafslien, Michael D Ohalleran, Patrick Miles and Peter Michael Leddy. View Insider Buying and Selling for NuVasive.

How do I buy shares of NuVasive?

Shares of NUVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NuVasive's stock price today?

One share of NUVA stock can currently be purchased for approximately $49.76.

How big of a company is NuVasive?

NuVasive has a market capitalization of $2.54 billion and generates $1.03 billion in revenue each year. The medical device company earns $83 million in net income (profit) each year or $1.91 on an earnings per share basis. NuVasive employs 2,600 workers across the globe.

How can I contact NuVasive?

NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-909-1800 or via email at [email protected]


MarketBeat Community Rating for NuVasive (NUVA)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  575 (Vote Outperform)
Underperform Votes:  458 (Vote Underperform)
Total Votes:  1,033
MarketBeat's community ratings are surveys of what our community members think about NuVasive and other stocks. Vote "Outperform" if you believe NUVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NUVA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

NuVasive (NASDAQ:NUVA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
16 Wall Street analysts have issued ratings and price targets for NuVasive in the last 12 months. Their average twelve-month price target is $66.5333, suggesting that the stock has a possible upside of 33.71%. The high price target for NUVA is $90.00 and the low price target for NUVA is $47.00. There are currently 6 hold ratings and 10 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.632.692.752.76
Ratings Breakdown: 0 Sell Rating(s)
6 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $66.5333$66.80$72.3333$72.3333
Price Target Upside: 33.71% upside24.53% upside48.01% upside27.50% upside

NuVasive (NASDAQ:NUVA) Consensus Price Target History

Price Target History for NuVasive (NASDAQ:NUVA)

NuVasive (NASDAQ:NUVA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/2/2018Needham & Company LLCReiterated RatingBuy ➝ Buy$70.00 ➝ $69.00HighView Rating Details
5/2/2018BMO Capital MarketsDowngradeOutperform ➝ Market Perform$69.00HighView Rating Details
5/2/2018BTIG ResearchReiterated RatingBuy$72.00HighView Rating Details
4/4/2018Goldman SachsInitiated CoverageNeutral ➝ Neutral$47.00MediumView Rating Details
2/27/2018Robert W. BairdReiterated RatingHold$55.00LowView Rating Details
2/27/2018CowenSet Price TargetBuy$62.00LowView Rating Details
2/27/2018BarclaysReiterated RatingOverweight ➝ Buy$66.00 ➝ $62.00LowView Rating Details
2/27/2018Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$67.00 ➝ $55.00HighView Rating Details
2/27/2018Leerink SwannBoost Price TargetMarket Perform ➝ Market Perform$51.00 ➝ $52.00LowView Rating Details
2/27/2018Canaccord GenuityLower Price TargetBuy ➝ Buy$81.00 ➝ $73.00LowView Rating Details
1/17/2018Wells Fargo & CoDowngradeOutperform ➝ Market Perform$65.00MediumView Rating Details
1/9/2018Piper Jaffray CompaniesReiterated RatingBuy$90.00HighView Rating Details
11/10/2017Royal Bank of CanadaLower Price TargetOutperform ➝ Outperform$75.00 ➝ $70.00N/AView Rating Details
10/25/2017JPMorgan ChaseSet Price TargetBuy$78.00N/AView Rating Details
10/3/2017Jefferies GroupReiterated RatingBuy$79.00LowView Rating Details
9/21/2017GabelliReiterated RatingBuyLowView Rating Details
3/20/2017UBSReiterated RatingBuy$82.00N/AView Rating Details
11/30/2016AegisInitiated CoverageBuy$72.00N/AView Rating Details
7/27/2016Brean CapitalBoost Price TargetBuy$60.00 ➝ $70.00N/AView Rating Details
(Data available from 5/23/2016 forward)

Earnings

NuVasive (NASDAQ:NUVA) Earnings History and Estimates Chart

Earnings by Quarter for NuVasive (NASDAQ:NUVA)

NuVasive (NASDAQ:NUVA) Earnings Estimates

2018 EPS Consensus Estimate: $2.51
2019 EPS Consensus Estimate: $2.68
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$0.44$0.49$0.46
Q2 20184$0.55$0.62$0.59
Q3 20184$0.60$0.67$0.63
Q4 20184$0.76$0.89$0.84
Q1 20192$0.45$0.56$0.51
Q2 20192$0.63$0.64$0.64
Q3 20192$0.64$0.72$0.68
Q4 20192$0.75$0.96$0.86

NuVasive (NASDAQ NUVA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/25/2018$0.60N/AView Earnings Details
5/1/2018Q1 2018$0.45$0.39$259.43 million$260.50 millionViewListenView Earnings Details
2/26/2018Q4 2017$0.56$0.56$272.11 million$271.70 millionViewListenView Earnings Details
10/24/2017Q3 2017$0.48$0.52$255.70 million$247.40 millionViewN/AView Earnings Details
7/27/2017Q2 2017$0.4440$0.46$261.95 million$260.60 millionViewN/AView Earnings Details
4/25/2017Q1 2017$0.37$0.38$250.52 million$249.86 millionViewN/AView Earnings Details
2/9/2017Q416$0.51$0.53$261.25 million$271.10 millionViewListenView Earnings Details
10/25/2016Q316$0.40$0.40$243.49 million$239.60 millionViewListenView Earnings Details
7/26/2016Q216$0.36$0.40$232.86 million$236.50 millionViewListenView Earnings Details
4/26/2016Q116$0.27$0.31$205.54 million$215.10 millionViewListenView Earnings Details
2/11/2016Q415$0.31$0.35$215.08 million$215.30 millionViewListenView Earnings Details
10/27/2015Q315$0.27$0.35$200.21 million$200.50 millionViewListenView Earnings Details
7/28/2015Q215$0.25$0.31$200.71 million$202.91 millionViewListenView Earnings Details
5/4/2015Q115$0.21$0.30$189.30 million$192.40 millionViewListenView Earnings Details
2/24/2015Q4$0.37$0.39$201.40 million$204.30 millionViewListenView Earnings Details
10/30/2014Q314$0.14$0.09$179.30 million$189.90 millionViewListenView Earnings Details
7/29/2014Q214$0.25$0.28$177.50 million$190.70 millionViewListenView Earnings Details
4/29/2014Q114$0.13$0.29$171.30 million$177.50 millionViewListenView Earnings Details
3/3/2014Q413$0.32$0.37$181.24 million$190.80 millionViewListenView Earnings Details
10/29/2013Q313$0.24$0.39$158.30 million$169.20 millionViewListenView Earnings Details
7/30/2013Q2 2013$0.23$0.20$161.67 million$165.70 millionViewListenView Earnings Details
4/30/2013Q1 2013$0.22$0.26$157.34 million$159.50 millionViewListenView Earnings Details
2/26/2013Q4 2012$0.21$0.34$156.35 million$165.80 millionViewListenView Earnings Details
10/24/2012$0.21$0.23ViewN/AView Earnings Details
7/25/2012$0.23$0.27ViewN/AView Earnings Details
4/30/2012$0.18$0.20ViewN/AView Earnings Details
2/22/2012$0.22$0.27ViewN/AView Earnings Details
10/27/2011$0.24$0.26ViewN/AView Earnings Details
7/25/2011$0.28$0.30ViewN/AView Earnings Details
5/5/2011$0.19$0.24ViewN/AView Earnings Details
2/23/2011$0.42$0.46ViewN/AView Earnings Details
10/28/2010Q3 2010$0.26$0.29ViewN/AView Earnings Details
7/27/2010Q2 2010$0.18$0.24ViewN/AView Earnings Details
4/20/2010Q1 2010$0.07$0.09ViewN/AView Earnings Details
2/25/2010Q4 2009$0.11$0.11ViewN/AView Earnings Details
10/20/2009Q3 2009$0.05$0.15ViewN/AView Earnings Details
7/23/2009Q2 2009($0.02)$0.07ViewN/AView Earnings Details
4/22/2009Q1 2009($0.20)($0.02)ViewN/AView Earnings Details
2/25/2009Q4 2008$0.12$0.16ViewN/AView Earnings Details
10/22/2008Q3 2008$0.01$0.04ViewN/AView Earnings Details
7/24/2008Q2 2008($0.03)($0.01)ViewN/AView Earnings Details
4/22/2008Q1 2008($0.10)($0.10)ViewN/AView Earnings Details
2/19/2008Q4 2007($0.04)($0.03)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

NuVasive (NASDAQ:NUVA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

NuVasive (NASDAQ NUVA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.95%
Insider Trading History for NuVasive (NASDAQ:NUVA)
Institutional Ownership by Quarter for NuVasive (NASDAQ:NUVA)

NuVasive (NASDAQ NUVA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/6/2018Gregory T LucierCEOBuy6,000$50.30$301,800.00View SEC Filing  
3/1/2018Gregory T LucierCEOBuy6,000$48.57$291,420.00View SEC Filing  
8/29/2017Gregory T LucierCEOBuy2,000$61.52$123,040.00View SEC Filing  
8/18/2017Lesley H. HoweDirectorSell3,970$64.64$256,620.80View SEC Filing  
8/17/2017Gregory T LucierCEOBuy5,000$66.22$331,100.00View SEC Filing  
8/1/2017Peter Michael LeddyEVPBuy7,850$63.88$501,458.00View SEC Filing  
3/8/2017Jason HannonInsiderSell24,840$74.22$1,843,624.80View SEC Filing  
2/14/2017Lesley H. HoweDirectorSell6,049$73.26$443,149.74View SEC Filing  
12/12/2016Matthew LinkInsiderSell10,303$67.99$700,500.97View SEC Filing  
11/4/2016Michael D OhalleranDirectorBuy4,200$58.26$244,692.00View SEC Filing  
11/2/2016Patrick MilesDirectorBuy16,967$58.97$1,000,543.99View SEC Filing  
11/1/2016Patrick MilesDirectorBuy16,667$59.00$983,353.00View SEC Filing  
10/31/2016Joan StafslienEVPBuy5,000$59.68$298,400.00View SEC Filing  
10/31/2016Michael D OhalleranDirectorBuy4,205$59.47$250,071.35View SEC Filing  
8/23/2016Jason HannonEVPSell2,625$64.80$170,100.00View SEC Filing  
8/2/2016Jason HannonEVPSell11,184$62.70$701,236.80View SEC Filing  
8/2/2016Lesley H. HoweDirectorSell3,602$62.44$224,908.88View SEC Filing  
7/20/2016Jason HannonEVPSell2,920$62.80$183,376.00View SEC Filing  
6/16/2016Jason HannonEVPSell14,534$57.57$836,722.3837,616View SEC Filing  
1/6/2016Patrick MilesCOOSell10,723$54.03$579,363.6931,646View SEC Filing  
12/16/2015Patrick MilesCOOSell9,127$52.56$479,715.1231,646View SEC Filing  
12/7/2015Quentin S BlackfordCFOSell15,000$51.10$766,500.002,599View SEC Filing  
12/3/2015Patrick MilesCOOSell5,873$52.51$308,391.2340,773View SEC Filing  
11/2/2015Patrick MilesCOOSell15,000$48.12$721,800.0032,627View SEC Filing  
10/5/2015Matthew LinkinsiderSell1,714$50.72$86,934.0853,089View SEC Filing  
10/3/2015Quentin S BlackfordCFOSell5,000$36.30$181,500.00View SEC Filing  
10/1/2015Patrick MilesCOOSell15,000$48.10$721,500.0047,627View SEC Filing  
9/8/2015Russell PowersEVPSell5,806$51.64$299,821.8462,024View SEC Filing  
9/2/2015Jason HannonEVPSell11,962$52.02$622,263.2418,565View SEC Filing  
9/1/2015Patrick MilesCOOSell15,000$52.03$780,450.0062,627View SEC Filing  
8/31/2015Patrick MilesCOOSell15,000$53.34$800,100.0062,627View SEC Filing  
7/20/2015Jason HannonEVPSell15,000$49.60$744,000.00View SEC Filing  
6/15/2015Gregory T LucierCEOBuy4,491$49.49$222,259.59View SEC Filing  
6/12/2015Gregory T LucierCEOBuy8,000$50.10$400,800.00View SEC Filing  
6/10/2015Gregory T LucierCEOBuy10,000$49.10$491,000.00View SEC Filing  
6/8/2015Gregory T LucierCEOBuy10,000$49.26$492,600.00View SEC Filing  
6/4/2015Gregory T LucierCEOBuy10,000$49.71$497,100.00View SEC Filing  
6/2/2015Gregory T LucierCEOBuy8,000$49.96$399,680.00View SEC Filing  
6/2/2015Patrick MilesCOOSell4,194$49.47$207,477.18View SEC Filing  
5/29/2015Jack R BlairDirectorSell3,703$50.16$185,742.48View SEC Filing  
5/28/2015Gregory T LucierCEOBuy34,000$49.25$1,674,500.00View SEC Filing  
5/28/2015Russell PowersEVPSell8,042$49.00$394,058.00View SEC Filing  
5/19/2015Patrick MilesCOOSell15,000$47.52$712,800.00View SEC Filing  
5/1/2015Russell PowersEVPSell11,881$45.21$537,140.01View SEC Filing  
4/24/2015Russell PowersEVPSell3,888$44.07$171,344.16View SEC Filing  
3/13/2015Patrick MilesCOOSell7,920$45.52$360,518.40View SEC Filing  
3/9/2015Alexis V LukianovCEOSell5,313$44.82$238,128.66View SEC Filing  
3/3/2015Matthew LinkInsiderSell7,500$44.46$333,450.00View SEC Filing  
3/2/2015Jason HannonEVPSell5,085$45.06$229,130.10View SEC Filing  
2/9/2015Alexis V LukianovCEOSell5,454$46.10$251,429.40View SEC Filing  
2/5/2015Matthew LinkInsiderSell4,078$45.77$186,650.06View SEC Filing  
2/3/2015Patrick MilesCOOSell15,000$45.53$682,950.00View SEC Filing  
1/28/2015Keith ValentineCOOSell6,970$46.96$327,311.20View SEC Filing  
1/12/2015Alexis V LukianovCEOSell7,452$49.69$370,289.88View SEC Filing  
1/5/2015Jason HannonEVPSell12,117$46.82$567,317.94View SEC Filing  
1/5/2015Patrick MilesInsiderSell15,000$46.61$699,150.00View SEC Filing  
12/30/2014Jason HannonEVPSell15,000$47.63$714,450.00View SEC Filing  
12/29/2014Jason HannonEVPSell3,146$47.57$149,655.22View SEC Filing  
12/24/2014Patrick MilesInsiderSell15,000$47.52$712,800.00View SEC Filing  
12/19/2014Keith ValentineCOOSell5,893$47.78$281,567.54View SEC Filing  
12/1/2014Keith ValentineCOOSell2,500$43.66$109,150.00View SEC Filing  
11/19/2014Keith ValentineCOOSell5,582$43.32$241,812.24View SEC Filing  
11/19/2014Quentin S BlackfordCFOSell7,698$43.41$334,170.18View SEC Filing  
11/7/2014Alexis V LukianovCEOSell25,000$41.40$1,035,000.00View SEC Filing  
11/3/2014Keith ValentineCOOSell2,500$40.61$101,525.00View SEC Filing  
10/2/2014Keith ValentineCOOSell2,500$35.00$87,500.00View SEC Filing  
9/2/2014Keith ValentineCOOSell2,500$35.14$87,850.00View SEC Filing  
8/1/2014Keith ValentineCOOSell2,500$37.11$92,775.00View SEC Filing  
8/1/2014Michael LambertCFOSell4,010$37.11$148,811.10View SEC Filing  
7/30/2014Jason HannonEVPSell5,000$39.00$195,000.00View SEC Filing  
7/10/2014Russell PowersEVPSell3,200$33.43$106,976.00View SEC Filing  
7/1/2014Keith ValentineCOOSell2,500$35.65$89,125.00View SEC Filing  
7/1/2014Michael LambertCFOSell23,225$35.48$824,023.00View SEC Filing  
6/20/2014Keith ValentineCOOSell5,000$35.00$175,000.00View SEC Filing  
6/20/2014Russell PowersEVPSell9,526$35.00$333,410.00View SEC Filing  
5/5/2014Robert HuntDirectorSell20,000$34.25$685,000.0034,500View SEC Filing  
5/2/2014Michael LambertCFOSell13,096$33.07$433,084.7251,695View SEC Filing  
4/1/2014Keith ValentineCOOSell2,500$38.41$96,025.0088,985View SEC Filing  
3/11/2014Peter FarrellDirectorSell48,000$36.88$1,770,240.006,794View SEC Filing  
1/21/2014Jason HannonEVPSell10,095$36.60$369,477.008,899View SEC Filing  
1/16/2014Keith ValentineCOOSell20,000$37.96$759,200.0044,226View SEC Filing  
1/7/2014Alexis LukianovCEOSell34,217$34.29$1,173,300.9355,740View SEC Filing  
1/7/2014Craig HunsakerSVPSell4,980$35.00$174,300.0021,142View SEC Filing  
12/30/2013Craig HunsakerSVPSell4,275$32.10$137,227.5024,980View SEC Filing  
12/23/2013Michael LambertCFOSell17,091$32.49$555,286.5913,096View SEC Filing  
11/7/2013Alexis LukianovCEOSell5,000$31.45$157,250.0072,827View SEC Filing  
10/30/2013Jason HannonEVPSell2,334$28.90$67,452.60View SEC Filing  
10/30/2013Patrick MilesInsiderSell21,223$31.10$660,035.30View SEC Filing  
10/28/2013Patrick MilesInsiderSell7,331$25.72$188,553.32View SEC Filing  
10/21/2013Russell PowersVPSell12,500$25.39$317,375.00View SEC Filing  
10/11/2013Jason HannonEVPSell1,000$26.00$26,000.0019,991View SEC Filing  
10/7/2013Jason HannonEVPSell8,705$23.99$208,832.9519,991View SEC Filing  
10/7/2013Michael LambertCFOSell15,442$24.04$371,225.6830,187View SEC Filing  
8/6/2013Richard Treharne IIIDirectorBuy2,000$23.26$46,520.00View SEC Filing  
7/12/2013Craig E HunsakerSVPSell2,000$27.00$54,000.00View SEC Filing  
7/8/2013Alexis V LukianovCEOSell5,000$25.74$128,700.00View SEC Filing  
7/1/2013Keith ValentineCOOSell1,698$25.00$42,450.00View SEC Filing  
5/13/2013Alexis V LukianovCEOSell7,500$22.71$170,325.00View SEC Filing  
5/8/2013Peter Michael LeddyDirectorBuy2,400$22.24$53,376.00View SEC Filing  
5/7/2013Alexis V LukianovCEOSell12,500$22.11$276,375.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

NuVasive (NASDAQ NUVA) News Headlines

Source:
DateHeadline
Nuvasive SpineTRACK Registry Reaches Significant Enrollment Milestone Of 10000 PatientsNuvasive SpineTRACK Registry Reaches Significant Enrollment Milestone Of 10000 Patients
www.prnewswire.com - May 23 at 8:52 AM
Nuvasive SpineTRACK Registry Reaches Significant Enrollment Milestone Of 10,000 PatientsNuvasive SpineTRACK Registry Reaches Significant Enrollment Milestone Of 10,000 Patients
finance.yahoo.com - May 23 at 8:52 AM
K2M Disrupting The Market, Growing, And Still UndervaluedK2M Disrupting The Market, Growing, And Still Undervalued
seekingalpha.com - May 22 at 4:41 PM
NuVasive Not Getting, Or Deserving, The Benefit Of The Doubt YetNuVasive Not Getting, Or Deserving, The Benefit Of The Doubt Yet
seekingalpha.com - May 22 at 8:54 AM
NuVasive PRECICE STRYDE™ System Used In First Patient For Stature Lengthening By International Limb ...NuVasive PRECICE STRYDE™ System Used In First Patient For Stature Lengthening By International Limb ...
www.prnewswire.com - May 22 at 8:54 AM
NuVasive PRECICE STRYDE™ System Used In First Patient For Stature Lengthening By International Limb Lengthening ExpertNuVasive PRECICE STRYDE™ System Used In First Patient For Stature Lengthening By International Limb Lengthening Expert
finance.yahoo.com - May 22 at 8:54 AM
NuVasive, Inc. (NUVA) Expected to Post Quarterly Sales of $276.05 MillionNuVasive, Inc. (NUVA) Expected to Post Quarterly Sales of $276.05 Million
www.americanbankingnews.com - May 22 at 4:02 AM
 Brokerages Anticipate NuVasive, Inc. (NUVA) Will Post Earnings of $0.58 Per Share Brokerages Anticipate NuVasive, Inc. (NUVA) Will Post Earnings of $0.58 Per Share
www.americanbankingnews.com - May 20 at 11:16 AM
NuVasive Target of Unusually Large Options Trading (NUVA)NuVasive Target of Unusually Large Options Trading (NUVA)
www.americanbankingnews.com - May 18 at 6:46 AM
NuVasive Sponsors SOLAS 2018, Hosts Workshop On Latest Lateral InnovationsNuVasive Sponsors SOLAS 2018, Hosts Workshop On Latest Lateral Innovations
www.prnewswire.com - May 16 at 4:54 PM
NuVasive (NUVA) Cut to "Sell" at BidaskClubNuVasive (NUVA) Cut to "Sell" at BidaskClub
www.americanbankingnews.com - May 16 at 10:30 AM
NuVasive To Present At Bank Of America Conference; Webcast At 11:40 AM ETNuVasive To Present At Bank Of America Conference; Webcast At 11:40 AM ET
www.nasdaq.com - May 15 at 5:12 PM
NuVasive, Inc. (NUVA) Receives Average Rating of "Hold" from AnalystsNuVasive, Inc. (NUVA) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - May 13 at 7:52 PM
NuVasive, Inc. (NUVA) Short Interest Down 23.8% in AprilNuVasive, Inc. (NUVA) Short Interest Down 23.8% in April
www.americanbankingnews.com - May 13 at 1:40 AM
NuVasive To Present At The Bank of America Merrill Lynch 2018 Healthcare ConferenceNuVasive To Present At The Bank of America Merrill Lynch 2018 Healthcare Conference
finance.yahoo.com - May 9 at 4:53 PM
NuVasive Unveils Newest Additions To Early Onset Scoliosis Portfolio At POSNA Annual MeetingNuVasive Unveils Newest Additions To Early Onset Scoliosis Portfolio At POSNA Annual Meeting
finance.yahoo.com - May 8 at 4:52 PM
NuVasive, Inc. (NUVA) to Post Q2 2018 Earnings of $0.61 Per Share, William Blair ForecastsNuVasive, Inc. (NUVA) to Post Q2 2018 Earnings of $0.61 Per Share, William Blair Forecasts
www.americanbankingnews.com - May 7 at 1:54 AM
NuVasive, Inc. (NUVA) to Post Q4 2018 Earnings of $0.84 Per Share, William Blair ForecastsNuVasive, Inc. (NUVA) to Post Q4 2018 Earnings of $0.84 Per Share, William Blair Forecasts
www.americanbankingnews.com - May 4 at 8:37 AM
Q2 2018 Earnings Estimate for NuVasive, Inc. (NUVA) Issued By Leerink SwannQ2 2018 Earnings Estimate for NuVasive, Inc. (NUVA) Issued By Leerink Swann
www.americanbankingnews.com - May 4 at 7:31 AM
Q2 2018 Earnings Estimate for NuVasive, Inc. Issued By Jefferies Group (NUVA)Q2 2018 Earnings Estimate for NuVasive, Inc. Issued By Jefferies Group (NUVA)
www.americanbankingnews.com - May 4 at 7:31 AM
NuVasive, Inc. (NUVA) Expected to Announce Quarterly Sales of $277.17 MillionNuVasive, Inc. (NUVA) Expected to Announce Quarterly Sales of $277.17 Million
www.americanbankingnews.com - May 4 at 1:54 AM
Brokers Set Expectations for NuVasive, Inc.s FY2019 Earnings (NUVA)Brokers Set Expectations for NuVasive, Inc.'s FY2019 Earnings (NUVA)
www.americanbankingnews.com - May 3 at 9:57 AM
NuVasive, Inc. (NUVA) to Post Q3 2018 Earnings of $0.62 Per Share, Jefferies Group ForecastsNuVasive, Inc. (NUVA) to Post Q3 2018 Earnings of $0.62 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - May 3 at 9:19 AM
Analysts Issue Forecasts for NuVasive, Inc.s Q2 2018 Earnings (NUVA)Analysts Issue Forecasts for NuVasive, Inc.'s Q2 2018 Earnings (NUVA)
www.americanbankingnews.com - May 3 at 8:06 AM
NuVasive, Inc. (NUVA) Expected to Announce Earnings of $0.59 Per ShareNuVasive, Inc. (NUVA) Expected to Announce Earnings of $0.59 Per Share
www.americanbankingnews.com - May 2 at 11:16 PM
ValuEngine Lowers NuVasive (NUVA) to Strong SellValuEngine Lowers NuVasive (NUVA) to Strong Sell
www.americanbankingnews.com - May 2 at 11:11 PM
NuVasive (NUVA) Downgraded by BMO Capital Markets to Market PerformNuVasive (NUVA) Downgraded by BMO Capital Markets to Market Perform
www.americanbankingnews.com - May 2 at 11:10 AM
NuVasives (NUVA) Buy Rating Reaffirmed at Needham & Company LLCNuVasive's (NUVA) Buy Rating Reaffirmed at Needham & Company LLC
www.americanbankingnews.com - May 2 at 10:47 AM
The Key Reason NuVasive Lost Money Last QuarterThe Key Reason NuVasive Lost Money Last Quarter
www.fool.com - May 2 at 9:19 AM
NuVasive (NUVA) Q1 2018 Results - Earnings Call TranscriptNuVasive (NUVA) Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 2 at 9:01 AM
BRIEF-NuVasive Reports Q1 GAAP Loss Per Share Of $0.53BRIEF-NuVasive Reports Q1 GAAP Loss Per Share Of $0.53
www.reuters.com - May 2 at 9:01 AM
NuVasive (NUVA) Q1 Earnings Miss Estimates, Revenues In LineNuVasive (NUVA) Q1 Earnings Miss Estimates, Revenues In Line
www.zacks.com - May 2 at 9:01 AM
NuVasive, Inc. 2018 Q1 - Results - Earnings Call SlidesNuVasive, Inc. 2018 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 2 at 9:01 AM
Edited Transcript of NUVA earnings conference call or presentation 1-May-18 8:30pm GMTEdited Transcript of NUVA earnings conference call or presentation 1-May-18 8:30pm GMT
finance.yahoo.com - May 2 at 9:00 AM
NuVasive (NUVA) Given "Buy" Rating at BTIG ResearchNuVasive (NUVA) Given "Buy" Rating at BTIG Research
www.americanbankingnews.com - May 2 at 8:50 AM
NuVasive (NUVA) Announces Quarterly  Earnings ResultsNuVasive (NUVA) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 1 at 9:10 PM
NuVasive (NUVA) Issues FY18 Earnings GuidanceNuVasive (NUVA) Issues FY18 Earnings Guidance
www.americanbankingnews.com - May 1 at 6:32 PM
Earnings Reaction History: NuVasive, Inc., 44.4% Follow-Through Indicator, 5.9% SensitiveEarnings Reaction History: NuVasive, Inc., 44.4% Follow-Through Indicator, 5.9% Sensitive
www.nasdaq.com - May 1 at 4:42 PM
NuVasive Q1 18 Earnings Conference Call At 4:30 PM ETNuVasive Q1 18 Earnings Conference Call At 4:30 PM ET
www.nasdaq.com - May 1 at 4:42 PM
NuVasive: 1Q Earnings SnapshotNuVasive: 1Q Earnings Snapshot
finance.yahoo.com - May 1 at 4:42 PM
NuVasive Announces First Quarter 2018 Financial ResultsNuVasive Announces First Quarter 2018 Financial Results
www.prnewswire.com - May 1 at 4:10 PM
NuVasive (NUVA) Downgraded by Zacks Investment ResearchNuVasive (NUVA) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 1 at 12:26 PM
NuVasive, Inc. (NUVA) Sees Large Growth in Short InterestNuVasive, Inc. (NUVA) Sees Large Growth in Short Interest
www.americanbankingnews.com - April 26 at 2:22 AM
NuVasive Sponsors AANS 2018, Hosts Workshops And Presentations On Latest InnovationsNuVasive Sponsors AANS 2018, Hosts Workshops And Presentations On Latest Innovations
finance.yahoo.com - April 24 at 5:01 PM
NuVasive (NUVA) Scheduled to Post Earnings on TuesdayNuVasive (NUVA) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - April 24 at 9:36 AM
NuVasive (NUVA) Downgraded by BidaskClub to "Hold"NuVasive (NUVA) Downgraded by BidaskClub to "Hold"
www.americanbankingnews.com - April 21 at 7:24 AM
New Research: Key Drivers of Growth for NuVasive, Apptio, Apollo Investment, Uranium Energy, AECOM, and US ...New Research: Key Drivers of Growth for NuVasive, Apptio, Apollo Investment, Uranium Energy, AECOM, and US ...
globenewswire.com - April 19 at 9:00 AM
Investors Purchase Large Volume of Put Options on NuVasive (NUVA)Investors Purchase Large Volume of Put Options on NuVasive (NUVA)
www.americanbankingnews.com - April 19 at 8:32 AM
NuVasive, Inc. (NUVA) Receives Average Rating of "Buy" from BrokeragesNuVasive, Inc. (NUVA) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 18 at 7:24 PM
NuVasive, Inc. (NUVA) Expected to Announce Quarterly Sales of $260.48 MillionNuVasive, Inc. (NUVA) Expected to Announce Quarterly Sales of $260.48 Million
www.americanbankingnews.com - April 17 at 2:17 AM

SEC Filings

NuVasive (NASDAQ:NUVA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

NuVasive (NASDAQ:NUVA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

NuVasive (NASDAQ NUVA) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.